Clinical Trials Insight: 700038891

Trial Profile

Clinical Trials Insight: 700038891

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2008

At a glance

  • Drugs Interleukin-2 (Primary)
  • Indications Cancer metastases; Renal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors 3SBio
  • Most Recent Events

    • 18 Nov 2008 New trial record.
    • 10 Nov 2008 The company files for the approval of NuLeusin by the Chinese State Food and Drug Administration according to a 3SBio media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top